Skip to main content

Notice for tozinameran and famtozinameran (Pfizer Australia Pty Ltd)

Active ingredients
tozinameran and famtozinameran
Date of review outcome
Lapse date
Type
Provisional determination
Indication
Booster for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2
Therapeutic area
Infectious diseases

Help us improve the Therapeutic Goods Administration site